Background: Misbalances in extracellular matrix turnover are key factors in the devel-
| INTRODUCTION
Crohn's Disease is an inflammatory bowel disease showing a heterogeneous phenotype. The disease behavior can be classified according to the Montreal classification in nonstricturing/nonpenetrating (B1), stricturing (B2), and penetrating disease (B3). 1, 2 This phenotype can change over time. [3] [4] [5] It is thought that chronic inflammation and damage drives fibrosis and that a disturbed balance between extracellular matrix formation and degradation is responsible for the different phenotypes. Up to one-third of patients with Crohn's disease show signs of stricturing (ie, thickening of the wall of the intestinal lumen that causes stenosis) or penetrating (ie, formation of intra-abdominal fistulae, perforations or abscesses) disease at diagnosis. 6, 7 In up to 70% of the patients with Crohn's disease, chronic and long-standing disease results in complications when the disease shifts towards a stricturing or penetrating phenotype. 6, 8, 9 Penetrating vs stricturing phenotypes are proposed to reflect two opposing directions. 10 In the stricturing phenotype, excessive deposition of extracellular matrix by increased maturation of (myo)fibroblasts contributes to intestinal fibrogenesis and stenosis. 11 Penetrating disease on the other hand, results among others from excessive matrix metalloproteinase mediated destruction of extracellular matrix. Fistulae might occur due to reepithelialisation of penetrating ulcers that healed insufficiently because of increased matrix metalloproteinase activity. 12, 13 Extracellular matrix formation and degradation products can be measured in blood and could serve as biomarkers for stricturing or penetrating Crohn's disease. 2 The healthy intestine mainly consists of type I (68%), III (20%) and V (12%) collagen. 14 In the strictured intestine, both collagen content and the relative amount of type V collagen increases compared to control intestine. 14 During the early onset of fibrosis in the intestine, the ratio of type III collagen to type I collagen is increased.
In contrast, during the late stage of fibrosis, when active collagen deposition diminishes, the ratio of type III collagen to type I collagen decreases. 15 Type VI collagen is known to be both a component of the interstitial membrane, the basal lamina and of the basement membrane of the intestine. Furthermore, it is proposed to be a regulator of epithelial cell-fibronectin interactions. 16 Remodelling of extracellular matrix occurs mainly via matrix metalloproteinases. 17 Several subtypes of matrix metalloproteinases showed to be significantly upregulated in Crohn's disease and especially in penetrating disease. 17, 18 Among others matrix metalloproteinase-9, produced by neutrophils and macrophages, is upregulated in intestinal fistulae of patients with and without Crohn's disease. 13 Matrix metalloproteinase-9 inhibits wound healing and correlates with disease activity in Crohn's disease. 10, 19 Furthermore, matrix metaloproteinase-3 is markedly upregulated in fistulae of patients with Crohn's disease, independent of the inflammatory activity. 13 Biomarker assays measuring specific, neo-epitopes of degradation products of type I (matrix metalloproteinase-2, 9 and 13 degraded [C1M]), 20 type III (matrix metalloproteinase-9 degraded [C3M]), 21 type V (matrix metalloproteinase-2 and -9 degraded [C5M]) 22 and type VI (matrix metalloproteinase-2 and 9 degraded [C6M]) 23 collagen, and formation products of type I (P1NP), 24 III (Pro-C3), 25 V (Pro-C5) 26 and VI (Pro-C6) 27 collagen can be used as diagnostic tools for auto immune diseases (eg, ankylosing spondylitis) and in liver fibrosis (Table 1) . 22, 28 Neo-epitopes of degradation of extracellular matrix were able to differentiate between Crohn's disease, ulcerative colitis and non-Inflammatory Bowel Disease (IBD). 29 The aim of this study was to establish whether formation and degradation products of collagens type I, III, V and VI can serve as biomarkers to distinguish between nonstricturing/nonpenetrating, stricturing and penetrating Crohn's disease. Furthermore, we aimed to provide insight in collagen turnover in Crohn's disease with (CRP >5 mg/L) and without active inflammation.
| MATERIALS AND METHODS

| Study design and population
Serum from 112 patients with Crohn's disease was retrospectively collected from the database of the IBD centre of the University Medical Center Groningen (single centre) (Tables 2 and 4 inflammation (CRP <5 mg/L) based on the C-reactive protein (CRP)
level that was determined when the serum samples were taken (Table 3) . 30 All patients underwent standard work up including medical history, Harvey-Bradshaw (≤4 disease in remission, ≥5 active disease) index for assessing clinical disease activity, physical examination, ileocolonoscopy and pharmacological treatment. and -1 antigen, n-acetyltransferase, alanine aminotransferase, and syphilis by Food and Drug Administration-approved Methods.
| Biomarker assays
At Nordic Bioscience (Herlev, Denmark) neo-epitope fragments of extracellular matrix synthesis and degradation were assessed by solid phase competitive enzyme linked immunosorbent assays (ELISAs).
The markers included in this study are C1M, C3M, C5M, C6M, PINP, Pro-C3, Pro-C5 and Pro-C6 (Table 1) . 
| Ethical considerations
Patients gave written informed consent when participating in the University Medical Center Groningen IBD database for the use of patient data and serum.
3 | RESULTS
| Patient and controls demographics
This cohort contains 112 patients suffering from Crohn's disease and 24 healthy controls ( Table 2) . Patients with Crohn's disease were divided into nonstricturing/nonpenetrating (n=40), stricturing (n=55) and penetrating (n=17). Disease duration was significantly different Figure 2A ). For Pro-C6, C6M and their ratio, no significant differences were observed between patients with Crohn's disease and controls ( Figure 2B ). 
| DISCUSSION
The present study is the first to show that serum levels of formation and degradation products of collagens can be used to differentiate between penetrating vs nonstricturing/nonpenetrating and stricturing
Crohn's disease in the terminal ileum using a competitive ELISA system based on a extracellular matrix neo-epitope biomarker platform. 32 Furthermore, it is the first study that investigates serum markers for turnover of type V and VI collagen in Crohn's disease combined to the previously studied collagen type I and III. [33] [34] [35] Our study provides insight into the differences in turnover of extracellular matrix in the different phenotypes of Crohn's disease and compared this to healthy controls. Furthermore, by comparing Crohn's disease with and without elevated CRP, we provide insight into extracellular matrix turnover during active inflammation.
Our results show that penetrating Crohn's disease in the terminal ileum is characterised by increased matrix metalloproteinase-9 mediated breakdown of type III collagen (C3M) and that this is reflected in the serum of these patients (Figure 1) . A trend for increased matrix metalloproteinase-2/9/13 mediated type I collagen Crohn's disease compared to healthy colon, was previously reported by Kirkegaard et al. 13 Using gelatin zymography, they showed increased amounts of active matrix metalloproteinase-2 in Crohn's disease fistulae specimens compared to healthy colon. 13 Furthermore, Efsen et al. reported increased matrix metalloproteinase-3 and -9 activity in Crohn's disease fistulae compared to non-Crohn's disease fistulae. 36 Moreover, they reported that up to 50% of the total protease activity in Crohn's disease's fistulae is attributable to matrix metalloproteinases. 36 Increased C3M serum levels in patients with penetrating (Montreal B3) Crohn's disease, compared to nonstricturing/nonpenetrating and stricturing disease using the same markers was recently found in a Swiss IBD cohort as well. 37 Next to show a formation/degradation misbalance in penetrating Crohn's disease, we could show that active inflammation (defined by CRP >5 mg/L) leads to an altered collagen formation/degradation balance ( Figure 4 ).
During active inflammation, CRP is almost exclusively excreted by hepatocytes as part of the acute phase response upon stimulation by IL-6, TNFa and IL-1b originating at the site of inflammation.
30,38
Production of pro-inflammatory cytokines by innate immune cells like monocytes, neutrophils, mast cells, eosinophils and basophils goes along with production of matrix metalloproteinases at the site of inflammation and explains the increased levels of matrix metalloproteinase mediated degradation markers during active inflammation. 39, 40 CRP is a widely used marker to monitor disease activity in Crohn's disease, which correlates well with disease activity as well as with faecal calprotectin. 30 The association between a high number of flares and penetrating Crohn's disease has been reported before and is in line with the hypothesis that penetrating Crohn's disease is partly caused by matrix metalloproteinase-over activity. 5, 12 The association between marker levels and disease phenotype reported in this study was independent of the presence of active inflammation.
The overlap in increased matrix metalloproteinase activity in penetrating (reported in this study and previously) as well as in active
Crohn's Disease (this study) further confirms the importance to strive for mucosal healing (treat to target principle) in Crohn's disease patients to prevent complications.
We aimed to establish whether these collagen formation and degradation markers are able to distinguish between the subclasses of the Montreal disease behavior classification. According to the Montreal Behavior classification, patients are categorised into the class of the most severe phenotype (nonstricturing/nonpenetrating<stricturing<penetrating) they have had or have since they were diagnosed with Crohn's disease. 2 This comprises that patients in this study not necessarily had a stenosis or fistula when the serum sample was taken. Furthermore, this means that patients that were classified as penetrating could have had a history of stricturing disease.
To affirm that the differences in marker levels were due to the disease, patients were strictly selected. By only selecting patients with
Crohn's disease in the terminal ileum, the bulk of disease was limited to this anatomic region. The differences we observed are thereby due to differences in extracellular matrix turnover within this region and not due to large differences in disease affected intestine between, for example, patients with ileocolonic disease or only ileal disease. Furthermore, the included patients' disease behavior was stable during follow-up, which substantially confirms the Montreal behavior class in which they were classified. To rule out the effects of surgery, patients that had any kind of surgery 6 months before the sample was taken were not included. De Simone et al. previously showed that intestinal resection in Crohn's disease patients with active disease reduces serum levels of type III collagen formation markers 6 months after surgery compared to levels from serum taken just before surgery. 33 Furthermore, non-Crohn's disease related fibrotic and autoimmune disease, and all forms of malignancy (except for skin cancer and haematological disease) were excluded.
Interestingly, levels of formation markers for type I, III and VI col- collagens, laminin or fibronectin. 17 Stricturing of the intestine depends not only on excessive deposition of extracellular matrix but also on enhanced matrix stiffness by increased crosslinking in the extracellular matrix, which may contribute to the stricture becoming symptomatic. 41 Intra-abdominal fistulae are very often surrounded by fibrosis.
Therefore, patients with penetrating disease most likely partly overlap in biomarker profile with patients having stricturing disease.
However, these patients did develop penetrating disease, among others due to matrix metalloproteinase over activity. These fistulae, abscesses or perforations arose despite the thickened intestinal wall and therefore might have required even more inflammationmediated activity of matrix metalloproteinases compared to fistulae, abscesses or perforations that arose in a nonfibrosis affected intestinal wall. This hypothesis can only be validated in a prospective longitudinal cohort in which marker levels from before and after surgery can be correlated with the resected specimen.
Patients with perianal disease were not separately grouped in the final analysis since no differences in marker levels between patients with and without perianal disease within one Montreal behavior class were found. Furthermore, when comparing patients classified as nonstricturing/nonpenetrating to patients with nonstricturing/nonpenetrating, stricturing or penetrating disease with perianal disease, no differences were found. As previously reported, intra-abdominal fistulae are very often surrounded by fibrosis and the wall of the terminal ileum contains relatively more extracellular matrix compared to the wall of the anus. 42, 43 We therefore hypothesise that the quantity of matrix metalloproteinase-over activity (due to inflammation) needed to penetrate the (fibrotic) wall of the intestine is higher compared to the matrix metalloproteinase activity needed to penetrate the wall of the perianal region. Furthermore, matrix metalloproteinase degraded fragments released in the perianal region might not reach the systemic circulation as easily as degraded fragments from intra-abdominal fistulae. These reasons could explain why the existence of perianal disease cannot be observed using these markers. Smith et al. who studied the Vienna classification based on serological and genetic markers in 231 well-characterised
Crohn's disease patients found that patients with perianal fistulae or abscesses were different from those with intra-abdominal penetrating disease. 2, 4 However, they did not check for differences in formation or degradation products of collagen, or for levels of matrix metalloproteinases.
Previously hypothesised differences in pathophysiology between possibly ischaemic anastomotic strictures and more fibrotic primary intestinal strictures might appear in differences in marker levels in our study. In our cohort, 16 of the 55 patients with stricturing disease underwent one or more re-resections because of recurrent stenosis. No differences in marker levels between patients with stricturing disease with and without re-resection were observed. Furthermore, pathology reports of the re-resections were checked on the occurrence of ischaemia in the resected stenosis. In none of the 11 pathology reports that were retrospectively available, pathologists reported signs of ischaemia. Pathologists reported mainly active inflammation, granulomatous and fibrosis in the resected specimens.
The literature describes reduced blood flow in active Crohn's disease, compared to inactive Crohn's disease and controls. 44 However,
Angerson et al. showed that patients with Crohn's disease that developed higher grades of neo-terminal ileal recurrence (at least five aphthous ulcers) had similar levels of blood flow as patients with active Crohn's ileitis. These levels were lower than controls. 45 Furthermore, literature describing histopathology of intestinal re-resection specimens or the role of ischaemia on IBD pathogenesis, does not report a role for ischaemia specifically in recurrent Crohn's disease. 45, 46 On the basis of our observations and the literature, we are not convinced that ischaemia plays a specific role in recurrence of stenosis in Crohn's disease.
Since the study is retrospective, disease behavior was classified according to retrospectively available imaging (MRI, CT, X-ray with barium contrast), endoscopic images and reports and pathology reports of intestinal resections. Although we do believe that the current sub-classification is sound enough to establish whether these markers are able to differentiate between these phenotypes, it
would be superior to have data from cross-sectional imaging to confirm the current state of the disease. Another limitation to this study is the relatively small sample size, especially the group with penetrating disease. This causes lack of power to detect a sound effect of medication use, smoking behavior, age and disease duration on biomarker levels. Ideally this would be examined in a prospective longitudinal cohort. Furthermore, one cannot confirm whether these markers are only produced in the fistulating parts of the intestine, in the inflamed intestinal tissue of Crohn's disease patients with penetrating disease or if they derive from a secondary source. Patients with penetrating Crohn's disease generally suffer from more complicated and severe intestinal (but also extraintestinal) disease. 5 The combination of more severe intestinal and extraintestinal disease activity in penetrating Crohn's disease could also explain the increased matrix metalloproteinase mediated breakdown of collagens. 8 The collagen degradation markers used in this study are designed to target specific matrix metalloproteinase degraded protein peptides that derive from those parts of the body in which these matrix metalloproteinases are active because of the disease. 47 In conclusion, based on serological collagen formation and degra- | 37
